Background and Objective: The association between angiotensin-converting enzyme insertion/deletion gene polymorphism and lung cancer susceptibility is still being debated. This meta-analysis was performed to evaluate the relationship between angiotensin-converting enzyme insertion/deletion gene polymorphism and lung cancer risk. Method: Association studies were identified from the databases of PubMed and China Biological Medicine Database disc as of June 1, 2015, and eligible investigations were synthesized using meta-analysis method. Results: Ten investigations were identified for the analysis of association between angiotensin-converting enzyme insertion/deletion gene polymorphism and lung cancer risk. There was no a marked association between D allele/DD genotype and lung cancer susceptibility, and II genotype did not play a protective role against lung cancer risk in the overall population (D: odds ratio ¼ 1.05, 95% confidence interval: 0.88-1.26, P ¼ .58; DD: odds ratio ¼ 1.18, 95% confidence interval: 0.82-1.69, P ¼ .38; II: odds ratio ¼ 0.99, 95% confidence interval: 0.77-1.27, P ¼ .93). Furthermore, angiotensinconverting enzyme insertion/deletion gene polymorphism was not associated with lung cancer susceptibility in Asian population and in Caucasians. Conclusion: Angiotensin-converting enzyme insertion/deletion gene polymorphism was not associated with lung cancer susceptibility. However, more investigations are required to further clarify the association.
Introduction
Lung cancer is currently the leading cause of cancer-related death worldwide for both men and women. 1, 2 Some present reports have found that gene polymorphism was associated with the susceptibility of lung cancer. The angiotensinconverting enzyme (ACE) is a key zinc metallopeptidase, and it catalyzes the conversion of angiotensin I to angiotensin II, which is the main active product of the renin-angiotensinaldosterone system. 3 The ACE insertion/deletion (I/D) gene polymorphism is related to circulating and cellular ACE concentration, might be implicated in the etiology of lung cancer. However, the available evidence is weak at present, due to sparseness of data or disagreements among the reported investigations. The evidence from meta-analysis may be powerful when compared with the individual investigation. We performed this meta-analysis to investigate whether the ACE I/D gene polymorphism was associated with the onset of lung cancer.
Materials and Methods

Search Strategy for the Association of ACE I/D Gene Polymorphism With Hemorrhagic Stroke Risk
The relevant studies were searched from the electronic databases of PubMed and China Biological Medicine Database disc as of June 1, 2015. The retrieval strategy of (lung cancer) AND polymorphism AND (angiotensin converting enzyme OR ACE) was entered into these databases mentioned previously for search. Additional articles were recruited through references cited in the included articles.
Inclusion and Exclusion Criteria
Inclusion criteria. (1) The outcome had to be lung cancer;
(2) there had to be at least 2 comparison groups (lung cancer group vs control group); and (3) investigation should provide the detailed data of ACE genotype distribution.
Exclusion criteria. (1) Review articles and editorials; (2) case reports; (3) preliminary result not on ACE I/D gene polymorphism or lung cancer; and (4) investigating the role of ACE inhibitor to lung cancer disease.
Data Extraction and Synthesis
Two investigators independently extracted the following information from each eligible study: first author's surname, year of publication, and the number of cases and controls for ACE genotypes. Frequency of D allele was calculated for the lung cancer group and the control group from the corresponding genotype distribution. The results were compared, and disagreement was resolved by discussion.
Statistical Analysis
Cochrane Review Manager Version 5 (Cochrane Library, United Kingdom) was used to calculate the available data from each investigation. The pooled statistic was counted using the fixed-effects model, but a random-effects model was conducted when the P value of heterogeneity test was less than .1. Results were expressed as odds ratios (ORs) for dichotomous data, and 95% confidence intervals (CIs) were also calculated. P < .05 was required for the pooled OR to be statistically significant. I 2 was used to test the heterogeneity among the included studies. Sensitivity analysis was also performed by the source of the controls (population vs hospital) and sample size of case or control (<100 vs 100).
Results
Study Characteristics for This Meta-Analysis
Ten studies [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] were recruited into our investigation to study the relationship between ACE I/D gene polymorphism and lung cancer susceptibility. The data of our interest were extracted: first author's surname, year of publication, and the number of cases and controls for ACE genotype ( Table 1 ).
Association of ACE I/D Gene Polymorphism With Hemorrhagic Stroke Risk
In this meta-analysis, a marked association between D allele/ DD genotype and lung cancer susceptibility was not found, and the association between II genotype and lung cancer risk was also not found in the overall population (D: OR ¼ 1.05, 95% CI: 0.88-1.26, P ¼ .58; DD: OR ¼ 1.18, 95% CI: 0.82-1.69, P ¼ .38; II: OR ¼ 0.99, 95% CI: 0.77-1.27, P ¼ .93; Figure 1 and Table 2 ). Furthermore, ACE I/D gene polymorphism was not associated with lung cancer susceptibility in Asian population and in Caucasians ( Table 2 ).
Sensitivity Analysis
Sensitivity analysis according to the source of controls (population based vs hospital based) was performed. We found that controls from all the included studies were from population based, and the results were same as those mentioned in the overall population. Sensitivity analysis for the relationship between ACE I/D gene polymorphism and lung cancer risk was also performed according to the sample size of case (<100 vs 100). In the meta-analysis of sample size of case 100, we found that ACE I/D gene polymorphism was not associated with lung cancer susceptibility, and the results were similar to those from nonsensitivity analysis (Table 2 ). However, in the meta-analysis of sample size of case <100, ACE D allele was associated with lung cancer susceptibility, but this relationship for DD genotype and II genotype was not found ( Table 2) .
Testing for Publication Bias
There was no significant publication bias in the overall population (Begg: P ¼ .592, Egger: P ¼ .856; Figure 2 ).
Discussion
In our meta-analysis, the association of ACE I/D gene polymorphism with hemorrhagic stroke susceptibility was studied, and 10 studies were recruited for this meta-analysis. To achieve a satisfactory power, meta-analysis of multiple studies clearly has a role in offering an association with such potentials, and the results from meta-analysis might be more convincing when compared with those from separate studies. In our metaanalysis, we did not find the difference in the distribution of D allele, DD homozygous, and II genotype between the case group and control group in the overall population. Furthermore, ACE I/D gene polymorphism was not associated with lung cancer susceptibility in Asians and Caucasians. The results from sensitivity analysis according to control source were same as those in the nonsensitivity analysis. Furthermore, in the sensitivity analysis according to sample size of case 100, we found that ACE I/D gene polymorphism was not associated with lung cancer susceptibility. In the sensitivity analysis according to sample size of case <100, we found that ACE D allele was associated with lung cancer susceptibility, but this relationship for DD genotype and II genotype was not found. As far as we know, the small sample size might be easy to get a positive result, so it was difficult to draw a powerful conclusion. In the test of publication bias, there was no significant publication bias in the overall population. The results for the overall population might be robust to some extent. To sum up those mentioned previously, ACE I/D gene polymorphism might be not associated with lung cancer susceptibility. However, more studies should be performed to confirm it.
In a previous study, Wang et al 14 recruited 6 case-control studies, including 807 patients with lung cancer and 816 healthy controls, and suggested that the ACE gene I/D polymorphism may not be associated with the risk of lung cancer. Gao et al 10 performed a meta-analysis of ACE gene I/D polymorphism from 6 studies with 1183 patients with lung cancer and 1065 controls, and they failed to detect any significant association. Cheng et al 15 included 8 case-control studies related to the ACE gene I/D polymorphism and lung cancer and reported that the ACE gene I/D polymorphism was not associated with lung cancer. In our meta-analysis, we included more studies than the previous meta-analyses, and our metaanalysis also performed the sensitivity analysis and publication bias test. Our study also reported ACE I/D gene polymorphism was not associated with lung cancer risk. The results from our meta-analysis might be more robust.
In our study, combining the results in the nonsensitivity analysis, we might draw the conclusion that D allele/DD genotype was not a risk factor to predict the lung cancer susceptibility. However, these findings should be regarded cautiously because many other ingredients, such as heterogeneity of enrolled cases, limited statistical power, variable study designs, and different interventions, were closely related to affect the results. In order to explore whether there exists the exact association between ACE I/D gene polymorphism and lung cancer risk, further study is required. In conclusion, the results in our study supported that ACE I/ D gene polymorphism is not a significant genetic molecular marker to predict the lung cancer susceptibility. However, more case-control association investigations on larger, stratified populations are required to further clarify the role of ACE I/D gene polymorphism in lung cancer susceptibility.
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